Literature DB >> 1370795

Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line.

P Henttu1, S S Liao, P Vihko.   

Abstract

To better understand androgen-regulated gene expression in the prostate, we have used Northern blot analysis to study the effects of androgens and other steroid hormones on the steady state levels of several human prostatic mRNAs in the LNCaP cell line. Dihydrotestosterone (40 nM) as well as a synthetic androgen, R1881 (0.1 nM), increased the amounts of prostate-specific antigen (PSA) and human glandular kallikrein mRNAs; at the same time, the level of prostatic acid phosphatase (PAP) mRNA was down-regulated. Incubation of LNCaP cells with medium containing 0.1 or 1 microM R1881 for 3, 7, or 13 days resulted in up-regulation of PSA and human glandular kallikrein mRNAs and down-regulation of PAP mRNA. Thus, the two clinically important prostate-specific marker proteins are inversely regulated in this cell line. The level of human androgen receptor mRNA was also repressed by the androgen treatments. 17 beta-Estradiol and progesterone had effects similar to those of R1881 on gene expression in LNCaP cells. Our results show that the decrease in the amount of secreted PAP and the increase in the amount of secreted PSA caused by androgens and other steroid hormones in the LNCaP cells of epithelial origin are mediated by changes in the levels of the corresponding mRNAs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370795     DOI: 10.1210/endo.130.2.1370795

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

1.  Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.

Authors:  H Yu; E P Diamandis; M Levesque; M Giai; R Roagna; R Ponzone; P Sismondi; M Monne; C M Croce
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Rat acid phosphatase: overexpression of active, secreted enzyme by recombinant baculovirus-infected insect cells, molecular properties, and crystallization.

Authors:  P Vihko; R Kurkela; K Porvari; A Herrala; A Lindfors; Y Lindqvist; G Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

3.  Transcriptional repression of the alpha-subunit gene by androgen receptor occurs independently of DNA binding but requires the DNA-binding and ligand-binding domains of the receptor.

Authors:  L L Heckert; E M Wilson; J H Nilson
Journal:  Mol Endocrinol       Date:  1997-09

4.  Free/Total Serum Prostate-Specific Antigen Ratio in Women with Colorectal Cancer Has Prognostic Significance.

Authors:  Nüvit Duraker; Zeynep Civelek Çaynak; Didem Can Trabulus
Journal:  J Gastrointest Cancer       Date:  2017-03

Review 5.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

Review 6.  Prostate-specific antigen and androgen deprivation therapy.

Authors:  H C Ruckle; J E Oesterling
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

Review 7.  Emerging PSA-based tests to improve screening.

Authors:  Richard J Bryant; Hans Lilja
Journal:  Urol Clin North Am       Date:  2014-02-26       Impact factor: 2.241

8.  Detection of prostate-specific antigen immunoreactivity in breast tumors.

Authors:  E P Diamandis; H Yu; D J Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.

Authors:  Salma Siddiqui; Stephen J Libertini; Christopher A Lucas; Alan P Lombard; Han Bit Baek; Rachel M Nakagawa; Kristine S Nishida; Thomas M Steele; Frank U Melgoza; Alexander D Borowsky; Blythe P Durbin-Johnson; LiHong Qi; Paramita M Ghosh; Maria Mudryj
Journal:  Cancer Lett       Date:  2020-04-21       Impact factor: 8.679

10.  Current status of 5α-reductase inhibitors in prostate disease management.

Authors:  Dong Il Kang; Jae Il Chung
Journal:  Korean J Urol       Date:  2013-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.